You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient and treatment characteristics of cases and controls

From: Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy

  Cases N = 26 (%) Controls N = 44 (%) Total N = 70 (%) Comparison of cases & controls p-value
Age when blood sample taken 66.3 (9.4) 65.5 (7.0) 65.8 (7.9) 0.7202
(years): Mean (SD)
Time since radiotherapy 10.2 (1.2) 9.8 (0.8) 9.9 (0.9) 0.1432
(years): Mean (SD)
Radiotherapy schedule     0.141
50 Gy in 25Fr 10 (38.5) 9 (20.4) 19 (27.1)
41.6 Gy in 13Fr 11 (42.3) 18 (40.9) 29 (41.4)
39 Gy in 13Fr 5 (19.2) 17 (38.6) 22 (31.4)
Tumour bed boost     0.6643
No 3 (11.5) 3 (6.8) 6 (13.6)
Yes 23 (88.5) 41 (93.2) 64 (91.4)
Lymphatic radiotherapy     0.7513,4
None 21 (80.8) 37 (84.1) 58 (82.9)
Axilla only 0 (0) 0 (0) 0 (0)
SCF only 5 (19.2) 6 (13.6) 11 (15.7)
Axilla and SCF 0 (0) 1 (2.3) 1 (1.4)
Adjuvant chemotherapy     0.861
No 17 (65.4) 31 (70.4) 48 (65.6)
Yes 9 (34.6) 13 (29.5) 22 (31.4)
Tamoxifen     0.4683
No 2 (7.7) 7 (15.9) 9 (12.9)
Yes 24 (92.3) 37 (84.1) 61 (87.1)  
  1. SD = standard deviation.
  2. Gy = Gray.
  3. Fr = fractions.
  4. SCF = supraclavicular fossa.
  5. 1p-value from chi-squared test unless otherwise indicated.
  6. 2p-value from t-test.
  7. 3Fisher’s exact test.
  8. 4chi-squared test of none versus any lymphatic radiotherapy.